Sonic Healthcare Limited
SHL
Rangering i aksjer
#2845
Sonic Healthcare Limited delivers medical diagnostic services to a diverse... Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory medicine and pathology testing, covering biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal diagnostics, toxicology, and other related functions. Furthermore, Sonic provides extensive radiology services, such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Its offerings also extend to primary care medical services, featuring general practice clinics, occupational health, specialized skin cancer clinics, after-hours GP services, IT solutions for general practices, and various community-based healthcare programs. Operating internationally, the company has a significant presence in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, and Belgium. Founded in 1934, Sonic Healthcare Limited is headquartered in Sydney, Australia.
Aksjekurs
$13.26
Markedsverdi
$6.55B
Endring (1 dag)
-0.21%
Endring (1 år)
-4.48%
Land
AU
Handel Sonic Healthcare Limited (SHL)
Kategori
Healthcare
P/E-forhold for Sonic Healthcare Limited (SHL)
P/E-forhold per October 2026 TTM: 15.03
Ifølge Sonic Healthcare Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 15.03. Ved slutten av 2024 hadde selskapet en P/E på 23.90.
P/E-forholdshistorikk for Sonic Healthcare Limited fra 2000 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 15.03 | -40.13% |
| 2025 | 25.11 | 5.04% |
| 2024 | 23.90 | -2.01% |
| 2023 | 24.39 | 125.74% |
| 2022 | 10.81 | -22.48% |
| 2021 | 13.94 | -49.09% |
| 2020 | 27.38 | 23.57% |
| 2019 | 22.16 | 1.75% |
| 2018 | 21.78 | -7.71% |
| 2017 | 23.59 | 20.42% |
| 2016 | 19.59 | -20.58% |
| 2015 | 24.67 | 36.98% |
| 2014 | 18.01 | 5.52% |
| 2013 | 17.07 | 8.95% |
| 2012 | 15.67 | -7.69% |
| 2011 | 16.97 | 22.94% |
| 2010 | 13.81 | -47.44% |
| 2009 | 26.27 | 35.39% |
| 2008 | 19.40 | -14.15% |
| 2007 | 22.60 | -4.90% |
| 2006 | 23.77 | -108.30% |
| 2005 | -286.19 | -96.99% |
| 2004 | -9.51K | -615.14% |
| 2003 | 1.85K | 142.10% |
| 2002 | 762.85 | -97.48% |
| 2001 | 30.27K | -9,768.14% |
| 2000 | -313.13 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 36.15 | 140.51% |
US
|
|
| 39.77 | 164.58% |
US
|
|
| -290.26 | -2,030.87% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 127.41% |
US
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.